do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline GLP-1-RA and inhibitors in the management of type 2 diabetes Clinical Use of DPP-4 Inhibitors

Tidal Wave of Litigation: Multiple lawsuits filed against Novo Nordisk and Eli Lilly have alleged that manufacturers failed to adequately warn patients and healthcare providers about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) and other vision-related complications associated with their products

GLP-1RA Cardiovascular Disease Outcomes Starting in 2008, the FDA began requiring all medications indicated for treatment of type 2 diabetes to evaluate cardiovascular risk reduction [45]

doi: 10.1016/j.molmet.2022.101641

In select cases particularly patients with: Obesity High insulin resistance Very high total daily insulin requirements endocrinologists may consider off-label use with: Continuous glucose monitoring Routine ketone monitoring Strict sick-day protocols Close specialist follow-up But this is not standard therapy

The following variables were included in a logistic regression model used to estimate propensity scores (PS): age, gender, pre-existing cardiovascular disease (coronary heart disease, stroke, transient ischemic attack, acute myocardial infarction, peripheral vascular disease) and heart failure